title: Borreliacidal activity of early Lyme disease sera against complement-resistant Borrelia afzelii FEM1 wild-type and an OspC-lacking FEM1 variant.
abstract: Sera obtained from 14 Lyme borreliosis patients at early stages (stages I and II) of the disease were examined for their borreliacidal properties against Borrelia afzelii isolate FEM1 by use of a growth inhibition assay. Five of 14 immune sera exhibited borreliacidal activity against isolate FEM1. Heat-inactivated immune sera failed to kill the spirochaetes. Immunoblotting experiments with outer-membrane preparations showed that OspC and 11 additional proteins of 14.0, 16.0, 17.7, 19.3, 21.7, 27.5, 32.7, 40.7, 48.9, 51.3 and 53.6 kDa were recognised by borreliacidal immune sera. To analyse the borreliacidal properties of anti-OspC antibodies, two sera (EM4 and EM5), which beside antibodies against a 51.3-kDa protein contained exclusively anti-OspC antibodies, were further investigated by comparative analysis with a FEM1 wild-type and a FEM1 variant lacking OspC in a growth inhibition assay. Only FEM1 wild-type and not variant FEM1OspC(-) was killed by immune sera EM4 and EM5. Complement-dependent killing of FEM1 wild-type was mediated by formation of the terminal complement complex that was found to be attached directly to the outer membrane as confirmed by immuno-electron microscopy. No complement deposition was observed on the surface of variant FEM1OspC(-) after incubation with immune sera EM4 and EM5, thereby suggesting that only anti-OspC antibodies in these two immune sera were responsible for borreliacidal activity. These results provide direct evidence that anti-OspC antibodies, once developed during the immune response, are of critical importance for efficient killing of borreliae in the early phase of infection.
authors.forename: Peter
authors.initials: P
authors.lastname: Kraiczy
authors.forename: Klaus-Peter
authors.initials: KP
authors.lastname: Hunfeld
authors.forename: Stefan
authors.initials: S
authors.lastname: Peters
authors.affiliation: Institute of Medical Microbiology, University Hospital Frankfurt, Paul-Ehrlich-Straße 40, D-60596 Frankfurt, Germany, *Institute of Hygiene, University of Innsbruck, Fritz-Pregl-Straße 3, A-6020 Innsbruck, Austria and †Department of Biological Electron Microscopy, University of Bayreuth, Universitätsstraße 30, D-95440 Bayreuth, Germany and ‡Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Pettenkoferstraße 9a, D-80336 München, Germany.
authors.forename: Reinhard
authors.initials: R
authors.lastname: Würzner
authors.affiliation: Institute of Medical Microbiology, University Hospital Frankfurt, Paul-Ehrlich-Straße 40, D-60596 Frankfurt, Germany, *Institute of Hygiene, University of Innsbruck, Fritz-Pregl-Straße 3, A-6020 Innsbruck, Austria and †Department of Biological Electron Microscopy, University of Bayreuth, Universitätsstraße 30, D-95440 Bayreuth, Germany and ‡Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Pettenkoferstraße 9a, D-80336 München, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Acker
authors.affiliation: Institute of Medical Microbiology, University Hospital Frankfurt, Paul-Ehrlich-Straße 40, D-60596 Frankfurt, Germany, *Institute of Hygiene, University of Innsbruck, Fritz-Pregl-Straße 3, A-6020 Innsbruck, Austria and †Department of Biological Electron Microscopy, University of Bayreuth, Universitätsstraße 30, D-95440 Bayreuth, Germany and ‡Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Pettenkoferstraße 9a, D-80336 München, Germany.
authors.forename: Bettina
authors.initials: B
authors.lastname: Wilske
authors.forename: Volker
authors.initials: V
authors.lastname: Brade
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology*; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins / Q000737:chemistry / Q000276:immunology / Q000302:isolation & purification; D001898:Borrelia / Q000254:growth & development / Q000276:immunology*; D003176:Complement C3 / Q000276:immunology; D003183:Complement C6 / Q000276:immunology; D003186:Complement C9 / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology*; D017931:DNA Primers / Q000737:chemistry; D004269:DNA, Bacterial / Q000737:chemistry; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005408:Flagellin / Q000737:chemistry; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D015151:Immunoblotting; D008193:Lyme Disease / Q000097:blood / Q000276:immunology*; D008854:Microscopy, Electron; D016253:Microscopy, Immunoelectron; D012329:RNA, Bacterial / Q000737:chemistry / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D003176:Complement C3; D003183:Complement C6; D003186:Complement C9; D017931:DNA Primers; D004269:DNA, Bacterial; D007106:Immune Sera; C079616:OspC protein; D012329:RNA, Bacterial; D005408:Flagellin; D003165:Complement System Proteins